LymPro launch is the base of our 2015 expectations

LymPro launch is the base of our 2015 expectations. Eltoprazine's phase 2b trial is the next layer of value. ESS adds an additonal layer. But MANF's future potential could create some "irrational exuberance" in the stock. If that happens, no one can really speculate where the pps will go. I still say we get above .20 cents by Feb 1st. But with the right surprises that are within the realm of possibility, $1.00 by April is not impossible. (Pre-RS)